Breast Cancer

  1. Ibrance (palbociclib)
    Ibrance (palbociclib)
    by Pfizer Limited
    for Breast Cancer
    €5,336.00
  2. Kisqali (ribociclib)
    Kisqali (ribociclib)
    by Novartis Europharm Limited
    for Breast Cancer
    €4,887.50
  3. Lynparza (olaparib)
    Lynparza (olaparib)
    by AstraZeneca AB
    for Breast Cancer, Gynaecological Cancer
    €6,619.40
  4. Perjeta (pertuzumab)
    Perjeta (pertuzumab)
    by Roche Registration Limited
    for Breast Cancer
    €2,869.25
View as Grid List

4 Items

per page
Set Descending Direction